DK3986561T3 - Pyrido[2,3-D]pyrimidin-derivater som inhibitorer af replikationen af human immundefektvirus - Google Patents

Pyrido[2,3-D]pyrimidin-derivater som inhibitorer af replikationen af human immundefektvirus Download PDF

Info

Publication number
DK3986561T3
DK3986561T3 DK20743783.1T DK20743783T DK3986561T3 DK 3986561 T3 DK3986561 T3 DK 3986561T3 DK 20743783 T DK20743783 T DK 20743783T DK 3986561 T3 DK3986561 T3 DK 3986561T3
Authority
DK
Denmark
Prior art keywords
pyrido
inhibitors
immunodeficiency virus
human immunodeficiency
virus replication
Prior art date
Application number
DK20743783.1T
Other languages
Danish (da)
English (en)
Inventor
Eric P Gillis
Christiana Iwuagwu
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71738195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3986561(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Application granted granted Critical
Publication of DK3986561T3 publication Critical patent/DK3986561T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK20743783.1T 2019-06-19 2020-06-17 Pyrido[2,3-D]pyrimidin-derivater som inhibitorer af replikationen af human immundefektvirus DK3986561T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863406P 2019-06-19 2019-06-19
PCT/IB2020/055653 WO2020254985A1 (en) 2019-06-19 2020-06-17 Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Publications (1)

Publication Number Publication Date
DK3986561T3 true DK3986561T3 (da) 2024-03-04

Family

ID=71738195

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20743783.1T DK3986561T3 (da) 2019-06-19 2020-06-17 Pyrido[2,3-D]pyrimidin-derivater som inhibitorer af replikationen af human immundefektvirus

Country Status (33)

Country Link
US (2) US12129255B2 (cg-RX-API-DMAC7.html)
EP (1) EP3986561B1 (cg-RX-API-DMAC7.html)
JP (1) JP7628512B2 (cg-RX-API-DMAC7.html)
KR (1) KR102932817B1 (cg-RX-API-DMAC7.html)
CN (2) CN114245795B (cg-RX-API-DMAC7.html)
AR (1) AR119174A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020295793B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021025655A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021003388A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017479A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210664A (cg-RX-API-DMAC7.html)
DK (1) DK3986561T3 (cg-RX-API-DMAC7.html)
ES (1) ES2974541T3 (cg-RX-API-DMAC7.html)
FI (1) FI3986561T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240501T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065762T2 (cg-RX-API-DMAC7.html)
IL (1) IL288750B2 (cg-RX-API-DMAC7.html)
LT (1) LT3986561T (cg-RX-API-DMAC7.html)
MA (1) MA56526B1 (cg-RX-API-DMAC7.html)
MD (1) MD3986561T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021016149A (cg-RX-API-DMAC7.html)
MY (1) MY206712A (cg-RX-API-DMAC7.html)
PE (1) PE20220510A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553180A1 (cg-RX-API-DMAC7.html)
PL (1) PL3986561T3 (cg-RX-API-DMAC7.html)
PT (1) PT3986561T (cg-RX-API-DMAC7.html)
RS (1) RS65304B1 (cg-RX-API-DMAC7.html)
SI (1) SI3986561T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400153T1 (cg-RX-API-DMAC7.html)
TW (1) TWI850403B (cg-RX-API-DMAC7.html)
UA (1) UA128967C2 (cg-RX-API-DMAC7.html)
UY (1) UY38755A (cg-RX-API-DMAC7.html)
WO (1) WO2020254985A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3986561B1 (en) 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
US12415771B2 (en) 2019-06-19 2025-09-16 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
AU2020358156B2 (en) * 2019-10-01 2024-06-06 Janssen Sciences Ireland Unlimited Company Method for treating HIV with cabotegravir and rilpivirine
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
WO2021176366A1 (en) * 2020-03-06 2021-09-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US12703699B2 (en) 2020-03-06 2026-08-11 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
EP4135702B1 (en) * 2020-04-15 2026-06-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
AU2022362855B2 (en) * 2021-10-13 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
PL364279A1 (en) 2001-02-02 2004-12-13 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US8318732B2 (en) * 2008-07-02 2012-11-27 Avexa Limited Compounds having antiviral properties
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
LT3347352T (lt) * 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
WO2018045150A1 (en) * 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
MA53973A (fr) * 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
EP3986561B1 (en) 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
HRP20240501T1 (hr) 2024-07-05
JP2022537047A (ja) 2022-08-23
UA128967C2 (uk) 2024-12-11
MX2021016149A (es) 2022-05-18
MA56526B1 (fr) 2024-05-31
MD3986561T2 (ro) 2024-06-30
PH12021553180A1 (en) 2022-11-07
RS65304B1 (sr) 2024-04-30
AU2020295793A1 (en) 2022-01-20
PE20220510A1 (es) 2022-04-07
MA56526A (fr) 2022-04-27
UY38755A (es) 2020-11-30
EP3986561A1 (en) 2022-04-27
CN119039288A (zh) 2024-11-29
LT3986561T (lt) 2024-04-25
TWI850403B (zh) 2024-08-01
AU2020295793B2 (en) 2023-07-06
WO2020254985A1 (en) 2020-12-24
SI3986561T1 (sl) 2024-04-30
IL288750B1 (en) 2024-12-01
PT3986561T (pt) 2024-03-15
CO2021017479A2 (es) 2022-04-19
US20210323967A1 (en) 2021-10-21
ES2974541T3 (es) 2024-06-27
US12129255B2 (en) 2024-10-29
KR102932817B1 (ko) 2026-03-04
IL288750B2 (en) 2025-04-01
IL288750A (en) 2022-02-01
TW202115055A (zh) 2021-04-16
EP3986561B1 (en) 2024-02-14
CR20210664A (es) 2022-01-21
JP7628512B2 (ja) 2025-02-10
CN114245795B (zh) 2024-08-06
BR112021025655A2 (pt) 2022-02-01
AR119174A1 (es) 2021-12-01
US20250019383A1 (en) 2025-01-16
HUE065762T2 (hu) 2024-06-28
SMT202400153T1 (it) 2024-05-14
CA3143136A1 (en) 2020-12-24
CL2021003388A1 (es) 2022-09-30
CN114245795A (zh) 2022-03-25
KR20220024608A (ko) 2022-03-03
MY206712A (en) 2025-01-03
PL3986561T3 (pl) 2024-06-10
FI3986561T3 (fi) 2024-05-02

Similar Documents

Publication Publication Date Title
LT3986561T (lt) Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai
DK3873884T3 (da) 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
DK3429591T3 (da) Substituerede thieno[2,3-D]pyrimidin-derivater som inhibitorer af Menin-MLL og fremgangsmåder til anvendelse
EP3774775B8 (en) 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
DK4139309T5 (da) [1,3]diazino[5,4-d]pyrimidiner som her2-inhibitorer
DK3784664T3 (da) 2-amino-pyridin- eller 2-amino-pyrimidinderivater som cyclinafhængige kinasehæmmere
CY1124800T1 (el) Παραγωγο πυριδο[3,4-d]πυριμιδινης και φαρμακευτικως αποδεκτο αλας αυτου
DK3419978T3 (da) Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
IL281924A (en) New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making
EA201792689A1 (ru) Производные 2-(пиразолопиридин-3-ил)пиримидина в качестве ингибиторов jak
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
IL289456A (en) Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds
EA201691554A1 (ru) 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа
DK3630724T3 (da) Substituerede indolinderivater som inhibitorer af virusreplikation af denguevirus
UA111804C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK)
ECSP17030878A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
HUE057549T2 (hu) Imidazo[1,2-a]pirimidinszármazékok, eljárás elõállításukra és alkalmazásaik
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
ZA201701214B (en) Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication
DK2861608T3 (da) Prodrug-derivater af (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamid
MX2019007339A (es) Compuestos de pirazolopirimidina y metodos de uso de los mismos.
EP4038064C0 (en) N-SUBSTITUTED 6-OXO-1,6-DIHYDROPYRIMIDINE-2-YL DERIVATIVES AS INHIBITORS OF HUMAN IMMUNO DEFICIENCY VIRUS REPLICATION
CL2018000363A1 (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana.
DK3083627T3 (da) [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis
MX381590B (es) Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico.